Guidelines for Abstract Submission
Dates for abstract submission:
September 10, 2025
With late fee dates for abstract submission:
October 10, 2025
Spot Registration for the conference:
Please see the table -
Guidelines for Abstract Submission
- Only abstracts that concern bacteriophages and antimicrobial resistance will be accepted for presentation.
- All abstracts must be written in English and submitted only once via this webpage by the presenting author, whose email address should be provided. A second email address may also be provided.
- The text requires proofreading for spelling, grammar, and scientific accuracy before submission. Corrections made after the deadline will not be accepted.
- Original research will be preferred.
- Please select the most suitable topic or field for your abstract. The organisers will allocate the accepted abstracts to relevant sessions according to the field of bacteriophage and antimicrobial resistance selected by the presenting author.
- Please indicate your preferred presentation type: oral, poster, or no preference. The organizers will notify the presenter regarding the acceptance of the abstract and whether it will be assigned as a talk or a poster.
- The presenting author must register for the conference after submitting the abstract.”
- All co-authors must approve the abstract’s content, which will be distributed, published, displayed online, and included in the ICBRAR-2025 SBRT abstract book.
- Abstracts may be published one week before the conference to allow attendees sufficient time for review.
- All oral sessions will be live-moderated with a Q&A, and the posters must be displayed on the boards provided by the local organisers.
- Acceptance of a submission will be subject to the approval of the scientific committee of ICBRAR-2025 only.
Abstract Submission Guidelines
- Format: Include the title, author names, their affiliations, and the abstract text, not exceeding one page.
- Title: Use title case, keep it concise yet informative.
- Authors: List authors in the format: First Name (optional additional initials), Family Name, in sequence. Underline the presenting author’s name. Include affiliations as the main university or organization and country, omitting departments or P.O. Box details.
- Abstract Text: Limit to 300 words. Exclude figures, tables, or references.
Poster Presentations Guidelines
EXAMPLE:
BACTERIOPHAGE THERAPY OF PAN-DRUG RESISTANT ORTHOPAEDIC IMPLANT ASSOCIATED KLEBSIELLA PNEUMONIAE SEPTICAEMIA
Gopal Nath, Alakh Narayan Singh
Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India
Bacteriophage therapy presents a promising alternative to traditional antibiotics, as phages target and kill bacteria, irrespective of their antibiotic resistance, and can effectively disrupt biofilms. A 60-year-old female patient, who had undergone a total hip replacement two years prior, experienced increasing discomfort and pain while walking in 2023. She was subsequently diagnosed with a cyst near the implant, roughly the size of a cricket ball. A cystectomy was performed on 22 October 2023. Following this, her wound became infected with a strain of K. pneumoniae that was resistant to all available antibiotics, including colistin. Her condition deteriorated, showing signs and symptoms of septicemia. Blood tests revealed procalcitonin levels at 5.25 ng/mL, CRP (quantitative) at 240.1 mg/mL, blood urea at 121 mg/dL, and serum creatinine at 3.5 mg/dl. The total leukocyte count was 28740 /µL, with a differential count of 87% polymorphs, 10% lymphocytes, 1% eosinophils, and 2% monocytes. A three-dose phage cocktail targeting K. pneumoniae was administered locally to the large wound surface, resulting in a reduction in serum procalcitonin from 5.23 ng/mL to 0.298 ng/mL after 72 hours of therapy. CRP levels decreased from 240.1 mg/mL to 71.4 mg/mL, blood urea fell from 121 mg/dL to 70 mg/dL, and serum creatinine decreased to normal levels. It is noteworthy that K. pneumoniae continued to be detected throughout the nearly 135 days of continuous phage therapy, albeit in very low numbers. This persistence highlights the longevity of the biofilm on the implant; no antibiotic can be safely administered for such an extended period without the risk of developing resistance and causing adverse effects on the human microbiome, particularly in cases involving K. pneumoniae. The patient fully recovered after 152 days of phage therapy.
Keywords: Bacteriophage; Klebsiella pneumoniae; Colistin; Biofilm; septicemia; Orthopedic-implant